Introduction Objectives: The objective of this study was to investigate the potential epidemiological impact of viral load (VL) monitoring and its cost-effectiveness in Vietnam, where transmitted HIV drug resistance (TDR) prevalence has increased from 5% to 5%–15% in the past decade.
Methods Using a population-based mathematical model driven by data from Vietnam, we simulated scenarios of various combinations of VL testing coverage, VL thresholds for second-line ART initiation and availability of HIV drug-resistance tests. We assessed the cost per disability-adjusted life year (DALY) averted for each scenario.
Results Projecting expected ART scale-up levels, to approximately double the number of people on ART by 2030, will lead to an estimated 18 510 cases (95% CI: 9120–34 600 cases) of TDR and 55 180 cases (95% CI: 40540–65 900 cases) of acquired drug resistance (ADR) in the absence of VL monitoring. This projection corresponds to a TDR prevalence of 16% (95% CI: 11%–24%) and ADR of 18% (95% CI: 15%–20%). Annual or biennial VL monitoring with 30% coverage is expected to relieve 12%–31% of TDR (2260–5860 cases), 25%–59% of ADR (9620–22 650 cases), 2%–6% of HIV-related deaths (360–880 cases) and 19270–51400 DALYs during 2015–30. The 30% coverage of VL monitoring is estimated to cost US$4848–5154 per DALY averted. The projected additional cost for implementing this strategy is US$105–268 million over 2015–30.
Conclusion Our study suggests that a programmatically achievable 30% coverage of VL monitoring can have considerable benefits for individuals and leads to population health benefits by reducing the overall national burden of HIV drug resistance. It is marginally cost-effective according to common willingness-to-pay thresholds.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.